Clinical Research

Clinical Research

Beneficial fatty acids contribute to cardiovascular health. The spectrum of heart-healthy essential fatty acids fish provide is one of the major motivators to consume more fish, or to consider supplementing with fish oil – and more specifically, with Norwegian extra-virgin salmon oil (EVSO) from Atlantic salmon.


In an age where consumer trust hinges on the quality of a source ingredient, MRM’s FreshOMEGA™ uses only the highest quality Norwegian source of OmeGo® extra-virgin salmon oil (EVSO), which not only offers the most wholesome oil available today, it also ensures consumers a full-spectrum of at least 17 beneficial fatty acids – including being high in naturally occurring Asthaxanthin, Docosapentaenoic Acid (DPA), Eicosapentaenoic Acid (EPA) and DHA, and other health-promoting poly- and mono-unsaturated fatty acids. The fact that we provide a traceable path to that source is just an added bonus.


But equally important to consumer confidence is the ability to measure a product’s overall effectiveness by way of scientific proof, and it is in the lab that OmeGo® EVSO used in FreshOMEGA™ performs exceptionally well.


Clinical Data


The effect of FreshOMEGA™ EVSO on cardiovascular health can be clinically supported in placebo-controlled lab trials that examine the actual OmeGo® extra-virgin salmon oil (EVSO) used in our product.


Numerous studies have shown that one’s cholesterol ratio, quantity of low-density lipoprotein (LDL), and triglyceride levels are acceptable, measurable biomarkers for calculating cardiovascular risk factors – particularly when paired alongside lifestyle and dietary habits.


New studies now support yet another marker for calculating cardiovascular risk:  Measured blood levels of the down-stream metabolite, oxidized low-density lipoprotein-beta-2-glycoprotein-1 (oxLDL-GP), which has been directly correlated with circulatory plaque formation (1).


Scientific data indicates that the pure, OmeGO® EVSO (extracted using a proprietary low-heat, gentle enzymatic method) lends a full-spectrum of nutrients and provides all the benefits of typical fish oil – such as normalizing plasma omega-3 and triglyceride levels – while providing the added benefit of helping to reduce blood levels of oxLDL-GP(2).


In a clinical trial to support the efficacy of OmeGO® EVSO, Twenty-eight subjects were available to evaluate the effects of the finished products on concentrations of OxLDL-GP(2). In comparison to EVSO capsules (500mg), were DHA Algal Oil Capsules (500mg), Omega-3 Fish Oil Capsules (500mg) and Sunflower Oil Capsules (500mg) as a control to be taken twice a day for 21 days(2).


Results were significant, showing OmeGO® EVSO was associated with the largest significant change in mean oxLDL-GP levels with an 11.7% decrease from baseline.(2), in comparison to the other beneficial fatty acid OmeGO® EVSO showed a statistically significant 1.88x and 3.25x greater effect at lowering oxLDL-GP as compared to DHA Algal Oil Capsules and Omega-3 Fish Oil Capsules respectively.(2).


What is known about OxLDL-GP:


  • OxLDL-GP is highly inflammatory with proatherogenic properties that promote endothelial dysfunction. Circulating OxLDL-GP has been reported to be a predictor of coronary disease in apparently healthy and middle-aged people, as well as in people with cardiovascular disease and diabetes. This makes OxLDL-GP a reliable biomarker for measuring cardiovascular risk factors, and supports the idea that one’s ability to reduce ox-LDL could lower major cardiovascular risk factors and improve heart and cardiovascular health(1).


  • With only 1,000 mg per day of Extra-Virgin Salmon Oil for 3 weeks, test subjects showed improvements in the reduction of oxidized low-density lipoprotein beta-2 glycoprotein-1 (OxLDL-GP) complex concentration over that of other oils(2). (see graph below)


  • Currently a more comprehensive follow-up study on this and other biomarkers that predict cardiovascular risk factors is in progress in 2012, using the extra-virgin salmon oil used in FreshOMEGA™ EVSO.

 Data for graph is from a clinical study entitled “A study to evaluate the effect of three polyunsaturated fatty acid oil containing capsules to modulate serum circulatory oxidized low density lipoprotein-beta-2-glucoprotein-1 complex concentration.”


1.  “Oxidized-LDL/beta(2)-glycoprotein I complexes are associated with disease severity and increased risk for adverse outcomes in patients with acute coronary syndromes.” Greco TP, et al., American Journal Clinical Pathology, 2010, v.133, p737.


2. “A study to evaluate the effect of three polyunsaturated fatty acid oil containing capsules to modulate serum circulatory oxidized low density lipoprotein-beta-2-glycoprotein-1 complex concentration.” Dr. P. Kerkar and Dr. N. Sen, Recon Oil Industries Pvt. Ltd. personal communication, used with permission.